CN103408400B - 一种肌醇晶体及其制备方法和用途 - Google Patents
一种肌醇晶体及其制备方法和用途 Download PDFInfo
- Publication number
- CN103408400B CN103408400B CN201310409039.4A CN201310409039A CN103408400B CN 103408400 B CN103408400 B CN 103408400B CN 201310409039 A CN201310409039 A CN 201310409039A CN 103408400 B CN103408400 B CN 103408400B
- Authority
- CN
- China
- Prior art keywords
- inositol
- crystal formation
- crystal
- xrpd
- ray powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000013078 crystal Substances 0.000 title claims abstract description 111
- 229960000367 inositol Drugs 0.000 title claims abstract description 81
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 title claims abstract description 81
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 title claims abstract description 80
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 title claims abstract description 80
- 238000004519 manufacturing process Methods 0.000 title abstract description 5
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 68
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 33
- 238000000034 method Methods 0.000 claims description 21
- 238000000113 differential scanning calorimetry Methods 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 238000002844 melting Methods 0.000 claims description 15
- 230000008018 melting Effects 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 5
- 150000004001 inositols Chemical class 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 208000004930 Fatty Liver Diseases 0.000 claims description 4
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 4
- 208000010706 fatty liver disease Diseases 0.000 claims description 4
- 231100000240 steatosis hepatitis Toxicity 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 3
- 229930182558 Sterol Natural products 0.000 claims 1
- 150000003432 sterols Chemical class 0.000 claims 1
- 235000003702 sterols Nutrition 0.000 claims 1
- 238000001228 spectrum Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 238000001069 Raman spectroscopy Methods 0.000 description 8
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002329 infrared spectrum Methods 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 238000001237 Raman spectrum Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 241001499448 Heliodoxa imperatrix Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 238000001530 Raman microscopy Methods 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000012912 drug discovery process Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- -1 flavouring Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000003995 melancholia Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000003405 preventing effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229960001520 ranitidine hydrochloride Drugs 0.000 description 1
- GGWBHVILAJZWKJ-KJEVSKRMSA-N ranitidine hydrochloride Chemical compound [H+].[Cl-].[O-][N+](=O)\C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 GGWBHVILAJZWKJ-KJEVSKRMSA-N 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001931 thermography Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C29/00—Preparation of compounds having hydroxy or O-metal groups bound to a carbon atom not belonging to a six-membered aromatic ring
- C07C29/74—Separation; Purification; Use of additives, e.g. for stabilisation
- C07C29/76—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment
- C07C29/78—Separation; Purification; Use of additives, e.g. for stabilisation by physical treatment by condensation or crystallisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (9)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310409039.4A CN103408400B (zh) | 2013-09-10 | 2013-09-10 | 一种肌醇晶体及其制备方法和用途 |
PCT/CN2014/080912 WO2015035817A1 (zh) | 2013-09-10 | 2014-06-27 | 一种肌醇晶体及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310409039.4A CN103408400B (zh) | 2013-09-10 | 2013-09-10 | 一种肌醇晶体及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103408400A CN103408400A (zh) | 2013-11-27 |
CN103408400B true CN103408400B (zh) | 2018-02-02 |
Family
ID=49601459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310409039.4A Active CN103408400B (zh) | 2013-09-10 | 2013-09-10 | 一种肌醇晶体及其制备方法和用途 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN103408400B (zh) |
WO (1) | WO2015035817A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105669376B (zh) * | 2016-02-27 | 2019-03-12 | 诸城市浩天药业有限公司 | 制备高结晶度、粒径大的肌醇的结晶工艺及应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1045965A (zh) * | 1989-03-25 | 1990-10-10 | 李艺 | 非冷冻法生产肌醇的工艺 |
CN1267657A (zh) * | 2000-03-09 | 2000-09-27 | 镇万鑫 | 肌醇生产方法 |
CN1406916A (zh) * | 2001-08-29 | 2003-04-02 | 朱群乔 | 肌醇生产工艺 |
CN101081803A (zh) * | 2006-05-29 | 2007-12-05 | 天津市汉沽区百发化工厂 | 环己六醇或称六烃环六烷的生产方法 |
CN101619015A (zh) * | 2008-12-15 | 2010-01-06 | 丁立孝 | 葡萄糖仿生法生产肌醇技术 |
CN102603487A (zh) * | 2012-02-20 | 2012-07-25 | 河南鑫源食品有限公司 | 从玉米浆中制备肌醇的方法 |
CN103130615A (zh) * | 2011-11-29 | 2013-06-05 | 唐雪 | 糠饼肌醇 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH1045647A (ja) * | 1996-07-30 | 1998-02-17 | Nisso Eng Kk | イノシトール無水結晶の製造方法 |
CN1211334C (zh) * | 2002-07-09 | 2005-07-20 | 胡中士 | 无色透明针状晶体肌醇的制取方法 |
-
2013
- 2013-09-10 CN CN201310409039.4A patent/CN103408400B/zh active Active
-
2014
- 2014-06-27 WO PCT/CN2014/080912 patent/WO2015035817A1/zh active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1045965A (zh) * | 1989-03-25 | 1990-10-10 | 李艺 | 非冷冻法生产肌醇的工艺 |
CN1267657A (zh) * | 2000-03-09 | 2000-09-27 | 镇万鑫 | 肌醇生产方法 |
CN1406916A (zh) * | 2001-08-29 | 2003-04-02 | 朱群乔 | 肌醇生产工艺 |
CN101081803A (zh) * | 2006-05-29 | 2007-12-05 | 天津市汉沽区百发化工厂 | 环己六醇或称六烃环六烷的生产方法 |
CN101619015A (zh) * | 2008-12-15 | 2010-01-06 | 丁立孝 | 葡萄糖仿生法生产肌醇技术 |
CN103130615A (zh) * | 2011-11-29 | 2013-06-05 | 唐雪 | 糠饼肌醇 |
CN102603487A (zh) * | 2012-02-20 | 2012-07-25 | 河南鑫源食品有限公司 | 从玉米浆中制备肌醇的方法 |
Also Published As
Publication number | Publication date |
---|---|
WO2015035817A1 (zh) | 2015-03-19 |
CN103408400A (zh) | 2013-11-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103833626B (zh) | 西达本胺的晶型及其制备方法与应用 | |
CN113527203A (zh) | 乐伐替尼甲磺酸盐的新晶型及其制备方法和用途 | |
CN105209437A (zh) | 心肌肌球蛋白激动剂的盐和制备盐的方法 | |
TW201213325A (en) | Crystalline forms of pyrimidio [6,1-A] isoquinolin-4-one compounds | |
CN107921021A (zh) | 结晶化合物 | |
CN103788075A (zh) | 一种胸苷磷酸化酶抑制剂的结晶形式及其制备方法 | |
CN106543072A (zh) | 匹莫范色林化合物 | |
O’Nolan et al. | Chloral hydrate polymorphs and cocrystal revisited: solving two pharmaceutical cold cases | |
CN103408400B (zh) | 一种肌醇晶体及其制备方法和用途 | |
CN105111164B (zh) | 精茚虫威的晶型 | |
CN103476742A (zh) | 阿戈美拉汀的新晶型ⅶ、其制备方法、应用和包含其的药物组合物 | |
JP2020504124A (ja) | (r)−4−ヒドロキシ−2−オキソ−1−ピロリジンアセトアミドの結晶形、その調製方法および使用 | |
CN104649969B (zh) | 一种替尼类药物的盐及其制备方法 | |
CN106543124A (zh) | 达格列净化合物 | |
CN104710425B (zh) | 一种替格瑞洛新结晶及其制备方法 | |
WO2016078587A1 (zh) | Lu AE58054的盐酸盐晶型A及其制备方法和用途 | |
CN110372575A (zh) | 一种二氢吡啶钙拮抗剂共晶体及其制备方法和应用 | |
CN107428686A (zh) | 尼达尼布二乙磺酸盐晶体及其制备方法和用途 | |
CN106478636B (zh) | 替格瑞洛晶型及制备方法 | |
CN101962387B (zh) | 一种新结晶形态的氯吡格雷硫酸氢盐及其制备方法 | |
CN105566314A (zh) | 一种盐酸替扎尼定化合物 | |
WO2014193887A1 (en) | Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5 d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders | |
CN109963855B (zh) | 一种btk激酶抑制剂的结晶形式及制备方法 | |
CN106397306B (zh) | 一种盐酸多奈哌齐晶型化合物及其制备方法 | |
CN105085593A (zh) | 瑞加德松的晶型及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Inositol crystal and its preparation method and Application Effective date of registration: 20211217 Granted publication date: 20180202 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd. Registration number: Y2021980015486 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20221215 Granted publication date: 20180202 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd. Registration number: Y2021980015486 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Inositol crystal and its preparation method and application Effective date of registration: 20221216 Granted publication date: 20180202 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd. Registration number: Y2022980027969 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20231127 Granted publication date: 20180202 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd. Registration number: Y2022980027969 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: A crystal of inositol and its preparation method and application Effective date of registration: 20231204 Granted publication date: 20180202 Pledgee: Shandong Zhucheng rural commercial bank Limited by Share Ltd. Pledgor: ZHUCHENG HAOTIAN PHARM Co.,Ltd. Registration number: Y2023980069152 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |